RAC Regulatory Affairs Certification Exam — Questions and Answers

Question 1: Which of the following scenarios BEST illustrates an effective use of a pre-submission meeting with FDA?

Submitting draft labeling for final approval prior to the official NDA submission
Seeking FDA feedback on a proposed clinical trial design and endpoints before initiating the pivotal study (Correct answer)
Asking FDA to commit to a specific approval date for an upcoming NDA
Requesting agency pre-approval of promotional materials before product launch

Correct answer: Seeking FDA feedback on a proposed clinical trial design and endpoints before initiating the pivotal study

Pre-submission (Pre-Sub) meetings are used to obtain FDA feedback on study designs, endpoints, and data requirements before resource-intensive pivotal studies begin.

Question 2: Under the Biosimilar pathway (351(k) of the PHS Act), what must an applicant demonstrate beyond showing no clinically meaningful differences from the reference product?

Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data (Correct answer)
That the biosimilar has the exact same amino acid sequence as the reference biological product
That the biosimilar is manufactured at the same facility as the reference product
That the reference product's patent has expired before filing

Correct answer: Biosimilarity based on analytical, nonclinical, and clinical data, and optionally 'interchangeability' requiring additional switching study data

Biosimilar applicants must demonstrate biosimilarity through a totality-of-evidence approach; the higher standard of 'interchangeability' requires additional switching studies showing no diminished safety or efficacy.

Question 3: In the context of regulatory strategic planning, what does 'regulatory intelligence' refer to?

The IQ testing of regulatory staff members
Classified government agency communications obtained through FOIA requests only
Systematic gathering and analysis of information about regulatory environments, agency precedents, and competitive approvals to inform strategy (Correct answer)
The internal audit of a company's regulatory compliance status

Correct answer: Systematic gathering and analysis of information about regulatory environments, agency precedents, and competitive approvals to inform strategy

Regulatory intelligence is the ongoing collection and analysis of external regulatory data—including guidances, approvals, and enforcement trends—to shape submission strategy and anticipate agency expectations.

Question 4: Under 21 CFR Part 601, what is the regulatory pathway for biosimilar products in the US?

351(k) of the Public Health Service Act (Correct answer)
505(b)(1) NDA
510(k) premarket notification
501(k) pathway

Correct answer: 351(k) of the Public Health Service Act

Section 351(k) of the Public Health Service Act, established by the BPCI Act, provides the regulatory pathway for biosimilar and interchangeable biological products.

Question 5: What is the purpose of Risk Evaluation and Mitigation Strategies (REMS)?

Simplify manufacturing
Ensure safe use of high-risk medications (Correct answer)
Speed up clinical trials
Encourage over-the-counter use

Correct answer: Ensure safe use of high-risk medications

Risk Evaluation and Mitigation Strategies (REMS) are programs required by the FDA for certain high-risk medications to ensure that the benefits of the drug outweigh its risks. REMS programs can include elements like patient registries, specialized training for prescribers, or restricted distribution systems. Their primary goal is to mitigate specific serious risks and promote the safe use of these drugs.

Question 6: In the context of EU MDR, what is a 'Periodic Summary Report' (PSR) and when can it substitute for individual serious incident reports?

A PSR is submitted annually to the European Medicines Agency
A PSR may be agreed upon with the competent authority to report similar recurring incidents in aggregate rather than individually (Correct answer)
A PSR is an internal document not submitted to regulators
A PSR replaces all individual incident reports for Class I devices

Correct answer: A PSR may be agreed upon with the competent authority to report similar recurring incidents in aggregate rather than individually

Under EU MDR Article 87(9), manufacturers may agree with competent authorities to submit a PSR in lieu of individual reports for similar, recurring serious incidents.

Question 7: What is the primary distinction between a Class I recall and a Class II recall under FDA's recall classification system?

Class I applies to manufacturers; Class II applies to distributors
Class I is voluntary; Class II is mandatory
Class I involves reasonable probability of serious health consequences; Class II involves temporary or reversible adverse health consequences (Correct answer)
Class I involves drugs; Class II involves devices

Correct answer: Class I involves reasonable probability of serious health consequences; Class II involves temporary or reversible adverse health consequences

Class I recalls involve products where use or exposure may cause serious adverse health consequences or death; Class II involves temporary or medically reversible effects.

Question 8: Under 21 CFR Part 312, a sponsor who transfers all obligations to a CRO must ensure which of the following?

FDA approval of the transfer is obtained before work begins
A written agreement describing the transfer of responsibilities exists (Correct answer)
The CRO must hold the IND in its own name
The original sponsor is fully relieved of all regulatory responsibility

Correct answer: A written agreement describing the transfer of responsibilities exists

21 CFR 312.52 requires a written agreement that specifies which sponsor obligations have been transferred to the CRO; the sponsor retains overall responsibility.

Question 9: Which of the following best describes a 'Type C' meeting with FDA during drug development?

A meeting to discuss special topics such as carcinogenicity protocols, pediatric study designs, or issues arising during review (Correct answer)
A pre-NDA meeting to confirm completeness of the submission package
An end-of-Phase 2 meeting to confirm the adequacy of Phase 3 plans
A pre-IND meeting to discuss whether clinical studies may proceed

Correct answer: A meeting to discuss special topics such as carcinogenicity protocols, pediatric study designs, or issues arising during review

Type C meetings cover any topic not included in Type A or B categories, such as carcinogenicity protocols, pediatric programs, or specific development questions.

Question 10: Under 21 CFR 807.87, which element is specifically required in the 510(k) submission to describe performance testing?

A summary of the clinical investigation
Performance data and testing protocols that demonstrate substantial equivalence (Correct answer)
An Environmental Impact Statement
A full quality management system audit report

Correct answer: Performance data and testing protocols that demonstrate substantial equivalence

21 CFR 807.87(e) requires performance data including test protocols and results that support the substantial equivalence determination.

Question 11: When building a regulatory strategy for a biosimilar product in the US, which reference product data source is MOST important to characterize during planning?

The reference listed drug's (RLD) approved labeling, clinical pharmacology, and safety database (Correct answer)
The FDA's prior approval history for other biosimilars in the class
The innovator's patent expiry timeline
The manufacturing site master file of the reference product

Correct answer: The reference listed drug's (RLD) approved labeling, clinical pharmacology, and safety database

Biosimilar development strategy centers on demonstrating no clinically meaningful differences from the RLD, making the RLD's labeling, PK/PD profile, and safety data foundational inputs.

Question 12: A regulatory team must decide between a single global clinical study or separate regional studies. What is the primary regulatory consideration favoring a global study?

Global studies always cost less than regional studies
Regional studies are not accepted by EMA under any circumstances
A single study with diverse populations can support submissions across multiple regions, avoiding bridging studies (Correct answer)
FDA requires global trials for all NDA submissions

Correct answer: A single study with diverse populations can support submissions across multiple regions, avoiding bridging studies

A well-designed global trial with diverse populations can satisfy multiple regulatory bodies simultaneously, avoiding the need for separate regional bridging studies and accelerating worldwide approval.

Question 13: Under the EU Medical Device Regulation (MDR 2017/745), which of the following is a primary objective of a Post-Market Clinical Follow-up (PMCF) plan?

To gather marketing data and user preferences for the next product generation.
To fulfill the reporting requirements for individual serious adverse events to competent authorities.
To replace the need for pre-market clinical investigation data for high-risk devices.
To proactively collect and evaluate clinical data to confirm the safety and performance of the device throughout its expected lifetime. (Correct answer)

Correct answer: To proactively collect and evaluate clinical data to confirm the safety and performance of the device throughout its expected lifetime.

The EU MDR, Annex XIV, Part B, defines Post-Market Clinical Follow-up (PMCF) as a continuous process to update the clinical evaluation. Its main purpose is to proactively gather clinical data on a CE-marked device to confirm its ongoing safety and performance and to ensure the continued acceptability of identified risks.

Question 14: A company is planning global market entry for a Class II medical device. Which regulatory pathway typically offers the fastest US market access?

De Novo classification
Humanitarian Device Exemption
510(k) with predicate (Correct answer)
PMA

Correct answer: 510(k) with predicate

A 510(k) submission demonstrating substantial equivalence to a legally marketed predicate device is the fastest pathway for Class II devices.

Question 15: In GCP, source documents are BEST described as:

Sponsor monitoring logs
CRFs completed by the investigator
Original records or certified copies from which CRF data are derived (Correct answer)
Protocol amendments signed by the PI

Correct answer: Original records or certified copies from which CRF data are derived

Source documents are original records (e.g., hospital charts, lab reports) or certified copies that serve as the basis for CRF entries.

Question 16: Under FDA's IND regulations, a sponsor must notify the agency and place a clinical hold if which situation arises?

The study budget is revised significantly
An unexpected serious adverse event suggests an unreasonable risk to subjects (Correct answer)
A contract research organization is replaced mid-study
A principal investigator changes institutions

Correct answer: An unexpected serious adverse event suggests an unreasonable risk to subjects

An unexpected serious adverse event (SUSAR) that suggests unreasonable risk to subjects triggers a clinical hold obligation under 21 CFR 312.

Question 17: A manufacturer becomes aware that a series of malfunctions with its infusion pump necessitates a nationwide field correction to prevent an unreasonable risk of substantial public harm. The company also has information reasonably suggesting these malfunctions may have contributed to a patient's death. According to 21 CFR 803, what is the mandatory reporting timeframe to the FDA for this event?

10 working days after initiating the field correction.
5 working days after becoming aware that a reportable event requires remedial action. (Correct answer)
30 calendar days after becoming aware of the event.
Within 24 hours via a phone call to the district office.

Correct answer: 5 working days after becoming aware that a reportable event requires remedial action.

According to 21 CFR 803.53, a manufacturer must submit a 5-day report if they become aware that a reportable event necessitates remedial action to prevent an unreasonable risk of substantial harm to the public health. The need for a nationwide field correction to prevent such harm triggers this expedited reporting requirement.

Question 18: A pharmaceutical sponsor has an active Investigational New Drug (IND) application for a product in Phase 2 clinical trials. According to FDA regulations (21 CFR 312.33), what must the sponsor submit to the FDA within 60 days of the anniversary date of the IND going into effect?

A complete Development Safety Update Report (DSUR)
An IND Annual Report (Correct answer)
A New Drug Application (NDA)
A 15-day Alert Report

Correct answer: An IND Annual Report

Under 21 CFR 312.33, sponsors are required to submit an IND Annual Report to the FDA. This report must be submitted within 60 days of the anniversary of the date the IND went into effect and should summarize the status of ongoing studies, provide a summary of the previous year's findings, and update any new information.

Question 19: Which provision of the FD&C Act allows FDA to require Risk Evaluation and Mitigation Strategies (REMS) for drugs that pose serious safety risks?

Section 351 of the Public Health Service Act
Prescription Drug User Fee Act (PDUFA) Section IV
Section 505-1, added by FDAAA 2007 (Correct answer)
Section 510(k) of the FD&C Act

Correct answer: Section 505-1, added by FDAAA 2007

Section 505-1 of the FD&C Act, added by the Food and Drug Administration Amendments Act of 2007 (FDAAA), grants FDA authority to require REMS for drugs with serious risks.

Question 20: Under the Orphan Drug Act, a drug or biologic may receive orphan designation in the US if it treats a disease affecting fewer than how many people?

200,000 people in the US (Correct answer)
500,000 people in the US
100,000 people in the US
1 million people in the US

Correct answer: 200,000 people in the US

The Orphan Drug Act defines a rare disease as one affecting fewer than 200,000 persons in the United States, or where recovery of development costs is unlikely.

Question 21: Under 21 CFR Part 820, which document must be established for each type of device and include or refer to the device specifications and production processes?

Device History Record (DHR)
Design History File (DHF)
Quality System Record (QSR)
Device Master Record (DMR) (Correct answer)

Correct answer: Device Master Record (DMR)

The Device Master Record (DMR) must be established and maintained for each type of device and includes all specifications and procedures required for production.

Question 22: What is the primary purpose of an Annual Product Review (APR) in pharmaceutical manufacturing?

To assess consistency of existing processes and identify improvements (Correct answer)
To document supplier qualification activities
To satisfy FDA pre-approval inspection requirements
To validate new manufacturing equipment

Correct answer: To assess consistency of existing processes and identify improvements

APRs evaluate the consistency of existing processes, quality of raw materials, and product quality to identify opportunities for improvement.

Question 23: Which of the following is NOT a recognized type of 510(k) submission?

Abbreviated 510(k)
Expedited 510(k) (Correct answer)
Traditional 510(k)
Special 510(k)

Correct answer: Expedited 510(k)

The three recognized 510(k) types are Traditional, Abbreviated, and Special; 'Expedited' is not an official 510(k) category.

Question 24: A pharmaceutical company becomes aware of new data confirming a causal link between its marketed drug and a previously unknown serious adverse reaction. To update the Prescribing Information to add a new warning, which is the MOST appropriate regulatory submission to the FDA?

An annual report.
A New Drug Application (NDA).
A Prior Approval Supplement (PAS).
A "Changes Being Effected" (CBE-0) supplement. (Correct answer)

Correct answer: A "Changes Being Effected" (CBE-0) supplement.

For critical safety-related labeling changes, such as adding or strengthening a contraindication, warning, precaution, or adverse reaction, regulations permit the submission of a "Changes Being Effected" (CBE-0) supplement. This allows the applicant to implement the change immediately upon the FDA's receipt of the supplement, ensuring rapid communication of important safety information. A PAS would require FDA approval before implementation, causing a delay.

Question 25: In strategic regulatory planning, 'lifecycle management' (LCM) refers to:

Tracking adverse event reporting timelines post-approval
The process of updating SOPs annually after product launch
Managing the product's supply chain from API to patient delivery
Systematic planning of post-approval changes, new indications, and line extensions to extend commercial value (Correct answer)

Correct answer: Systematic planning of post-approval changes, new indications, and line extensions to extend commercial value

Regulatory LCM encompasses proactively planning formulation changes, new indications, pediatric extensions, and other post-approval strategies that sustain and grow the product's market position.

Question 26: A sponsor receives an SAE report from an investigator on a Saturday. Under 21 CFR 312.32, fatal unexpected SUSARs must be reported to FDA within:

30 calendar days
24 hours
15 calendar days
7 calendar days (Correct answer)

Correct answer: 7 calendar days

Fatal or life-threatening unexpected serious adverse drug reactions must be reported to the FDA within 7 calendar days.

Question 27: What action must a manufacturer take when they identify that a previously distributed device is adulterated or misbranded under the FD&C Act but poses no health risk?

File a 5-day MDR with FDA
Initiate a market withdrawal to remove or correct the product (Correct answer)
Take no action because there is no health risk
Submit a Class I recall notification to FDA

Correct answer: Initiate a market withdrawal to remove or correct the product

When a product is adulterated or misbranded but poses no health risk, a market withdrawal (not a recall) is the appropriate action.

Question 28: Which ICH guideline provides a framework for assessing genotoxic impurities in pharmaceutical products, directly influencing regulatory submission strategy?

ICH Q3A
ICH E6
ICH S2
ICH M7 (Correct answer)

Correct answer: ICH M7

ICH M7 provides guidance on assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals, setting acceptable intake thresholds.

Question 29: Under the Special 510(k) program, what is the primary basis for demonstrating substantial equivalence?

New clinical data
Design controls under 21 CFR Part 820 (Correct answer)
An IDE study
Published performance standards

Correct answer: Design controls under 21 CFR Part 820

The Special 510(k) relies on design controls to demonstrate that device modifications do not affect safety or effectiveness.

Question 30: Under 21 CFR Part 820, which record tracks the production history of a specific finished device unit or lot?

Quality System Record (QSR)
Device History Record (DHR) (Correct answer)
Device Master Record (DMR)
Design History File (DHF)

Correct answer: Device History Record (DHR)

The Device History Record (DHR) demonstrates that each device was manufactured in accordance with the DMR and documents the production history of each unit or lot.

Question 31: In strategic planning for a generic drug, which factor most significantly determines the regulatory pathway in the US?

The manufacturing site's ISO certification status
Whether the active ingredient has been approved in Europe
The size of the patient population needing the drug
The brand drug's patent expiration date and market exclusivity status (Correct answer)

Correct answer: The brand drug's patent expiration date and market exclusivity status

Patent expiration and exclusivity periods (including 180-day exclusivity for first filers) are central to determining when and how a generic ANDA can be strategically filed.

Question 32: In EU strategic planning, what is the strategic rationale for using the 'Article 8(3)' full application pathway versus the 'Article 10' generic pathway?

Article 8(3) is used for new active substances requiring a complete independent dossier of safety and efficacy (Correct answer)
Article 10 requires more clinical data than Article 8(3)
Article 10 is faster for novel active substances with no reference product
Article 8(3) applies only to biosimilars

Correct answer: Article 8(3) is used for new active substances requiring a complete independent dossier of safety and efficacy

Article 8(3) requires a complete, independent application for new active substances where no reference product exists to rely upon, making it the pathway for true innovator products in the EU.

Question 33: Which regulatory pathway expedites the review of drugs for serious conditions in the U.S.?

Orphan Drug Act
Fast Track designation (Correct answer)
Hatch-Waxman Act
ANDA

Correct answer: Fast Track designation

Fast Track designation is an FDA program designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. This designation allows for more frequent communication with the FDA and, potentially, a rolling review of the application, aiming to get important new drugs to patients sooner.

Question 34: Which scenario best illustrates a 'regulatory arbitrage' strategy?

Launching first in a jurisdiction with a more flexible or faster pathway, using that approval to support other filings (Correct answer)
Filing identical applications simultaneously in all global markets
Avoiding submission in strict regulatory markets to reduce costs
Using a contract research organization in multiple countries to run trials simultaneously

Correct answer: Launching first in a jurisdiction with a more flexible or faster pathway, using that approval to support other filings

Regulatory arbitrage exploits differences in regional regulatory pathways or timelines to gain early market access and leverage that approval reference for subsequent global filings.

Question 35: Which EU MDR 2017/745 document must be updated at least every 5 years (for Class III devices, more frequently) and summarize the PMS conclusions?

Technical Documentation
Periodic Safety Update Report (PSUR) (Correct answer)
Summary of Safety and Clinical Performance (SSCP)
Declaration of Conformity

Correct answer: Periodic Safety Update Report (PSUR)

The PSUR, required under EU MDR Article 86, synthesizes post-market surveillance data and must be updated at defined intervals based on device risk class.

Question 36: Under 21 CFR Part 606, blood establishment labels must include which information to ensure traceability and safe transfusion?

The HLA typing results and infectious disease screening panel results in full
The recipient's name and blood type for direct cross-matching purposes
The donor identification number, product name, collection facility, expiration date, and ABO/Rh blood group (Correct answer)
The full name and medical history of the blood donor

Correct answer: The donor identification number, product name, collection facility, expiration date, and ABO/Rh blood group

21 CFR 606.121 mandates specific label elements for blood products including donor ID, product name, facility, expiration, and blood type to ensure safe and traceable transfusions.

Question 37: Design validation under 21 CFR Part 820 must be performed under which conditions?

Conditions specified by ISO 14971 risk management
Any conditions defined in the DMR
Laboratory conditions with accelerated aging
Simulated or actual use conditions (Correct answer)

Correct answer: Simulated or actual use conditions

§820.30(g) requires design validation to be performed under defined operating conditions on initial production units, lots, or batches, or their equivalents, using simulated or actual use conditions.

Question 38: When a regulatory strategy calls for pursuing Priority Review in the US, what additional planning is required compared to Standard Review?

Additional nonclinical toxicology studies beyond what Standard Review requires
Submission of a Risk Evaluation and Mitigation Strategy (REMS) before filing
Filing of a separate Priority Review application distinct from the NDA/BLA
More intensive FDA meeting interactions and readiness for a 6-month rather than 12-month review clock (Correct answer)

Correct answer: More intensive FDA meeting interactions and readiness for a 6-month rather than 12-month review clock

Priority Review compresses FDA's review goal to 6 months (versus 10-12 for Standard), requiring the regulatory team to be prepared for faster agency feedback cycles and accelerated internal decision-making.

Question 39: What is the strategic advantage of using a pre-submission meeting (Type B meeting) with FDA during drug development?

It allows sponsors to align on study designs, endpoints, and data requirements before costly investments (Correct answer)
It guarantees expedited review timelines post-submission
It substitutes for formal Phase 2 clinical trial requirements
It locks FDA into approving the submission without further review

Correct answer: It allows sponsors to align on study designs, endpoints, and data requirements before costly investments

Type B meetings (including End-of-Phase 2 and pre-NDA meetings) allow sponsors to gain FDA feedback on development plans before committing resources, reducing submission risk.

Question 40: A manufacturer wants to make a change to an approved production process. Under 21 CFR Part 820, which step is required before implementing the change?

Filing a PMA supplement with FDA
Notifying all distributors of the pending change
Obtaining a written waiver from the quality manager
Following documented change control procedures including verification or validation as appropriate (Correct answer)

Correct answer: Following documented change control procedures including verification or validation as appropriate

§820.70(b) requires that changes to production processes be documented and reviewed, with verification or validation as appropriate before implementation.

Question 41: A 510(k) submitter references a predicate device that was itself cleared through a 510(k). This is known as using a:

Chained predicate (Correct answer)
Primary predicate
Series predicate
Split predicate

Correct answer: Chained predicate

Chained predicates refer to using a device whose own clearance relied on a prior predicate, creating a chain of substantial equivalence going back to a pre-amendments device.

Question 42: In strategic regulatory planning, 'regulatory intelligence' refers to:

Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy (Correct answer)
Background checks on agency reviewers
AI-based tools that predict approval dates
Competitive intelligence on rival companies' pipelines

Correct answer: Systematic monitoring of agency guidance, decisions, and policy trends to inform strategy

Regulatory intelligence involves tracking agency guidance documents, precedent decisions, policy shifts, and advisory committee trends to proactively shape development strategy.

Question 43: Under 21 CFR Part 312, a Type B meeting with FDA is most commonly used to discuss:

IND safety reporting procedures
End-of-Phase 2 issues and pre-NDA/BLA discussions (Correct answer)
REMS program requirements after approval
Post-approval label changes

Correct answer: End-of-Phase 2 issues and pre-NDA/BLA discussions

Type B meetings include End-of-Phase 1, End-of-Phase 2, pre-NDA/BLA, and pre-BLA meetings — they are milestone meetings that occur at defined stages of drug development.

Question 44: Under 21 CFR Part 820, corrective actions must be verified or validated to ensure they are effective. This verification must be:

Performed by the quality manager only
Documented (Correct answer)
Completed within 30 days of identifying the nonconformance
Approved by the FDA prior to implementation

Correct answer: Documented

§820.100 requires that the activities related to corrective action, including verification of effectiveness, be documented.

Question 45: Under 21 CFR 56.114, multi-site studies may use a single IRB (sIRB) arrangement. This became mandatory for domestic cooperative research under:

Common Rule 1991 revision
NIH Policy effective January 25, 2018 (Correct answer)
21st Century Cures Act (2016)
FDAMA (1997)

Correct answer: NIH Policy effective January 25, 2018

The revised NIH Policy on the Use of a Single Institutional Review Board mandated sIRB review for NIH-funded multi-site domestic studies effective January 25, 2018.

Question 46: Which scenario would most likely require a new 510(k) rather than a Special 510(k)?

A change in sterilization method from ETO to gamma radiation (Correct answer)
A software update that corrects a minor user interface bug
A labeling update to clarify storage temperature
A change in packaging material not affecting sterility

Correct answer: A change in sterilization method from ETO to gamma radiation

A change in sterilization method can affect device safety and sterility assurance and typically requires a Traditional 510(k) with new performance data.

Question 47: A company discovers that a released product lot may be adulterated. What is the first regulatory obligation?

Conduct a full CAPA before notifying anyone
File a Prior Approval Supplement with FDA
Assess whether a recall or market withdrawal is required (Correct answer)
Destroy remaining inventory immediately

Correct answer: Assess whether a recall or market withdrawal is required

Upon discovering potential adulteration, the company must assess the situation and determine if a recall, market withdrawal, or other action is required under 21 CFR Part 7.

Question 48: A company wants to expand an approved drug's indication. Which US regulatory mechanism most strategically minimizes development burden if supportive data already exists?

File a new NDA under a different trade name
Seek a separate Biologics License Application (BLA)
Withdraw the original NDA and refile with expanded label
Submit a Prior Approval Supplement (PAS) or efficacy supplement to the existing NDA (Correct answer)

Correct answer: Submit a Prior Approval Supplement (PAS) or efficacy supplement to the existing NDA

An efficacy supplement (Prior Approval Supplement) to an existing NDA is the standard and most efficient pathway to expand approved indications using existing or new clinical data.

Question 49: What is the primary function of a Design History File (DHF) in the development of a medical device subject to 21 CFR Part 820?

It documents the clinical trial endpoints and protocol amendments for the device
It serves as the Device Master Record for manufacturing instructions
It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan (Correct answer)
It is FDA's internal review record generated during the 510(k) premarket review

Correct answer: It contains the records describing the design history of a finished device, demonstrating that the design was developed in accordance with the approved design plan

The DHF compiles all design control records for a device, providing objective evidence that the design development process met requirements under 21 CFR 820.30.

Question 50: When aligning cross-functional teams on a regulatory submission timeline, which planning technique BEST identifies tasks that could delay the overall project if not completed on time?

Risk matrix scoring
Critical path analysis (Correct answer)
Resource leveling
Stakeholder mapping

Correct answer: Critical path analysis

Critical path analysis identifies the sequence of dependent tasks that determines the minimum project duration and highlights tasks where any delay impacts the final deadline.

Question 51: In GMP terms, what distinguishes a 'critical process parameter' (CPP) from a general process parameter?

CPPs are only monitored during validation, not routine production
Variation in a CPP directly impacts a critical quality attribute of the product (Correct answer)
CPPs are defined by regulatory agencies, not manufacturers
CPPs require annual revalidation regardless of process changes

Correct answer: Variation in a CPP directly impacts a critical quality attribute of the product

A CPP is one whose variability has a direct impact on a critical quality attribute (CQA), making it essential to monitor and control during manufacturing.

Question 52: When must a sponsor submit a Safety Report (IND Safety Report) to the FDA during clinical trials?

Within 7 or 15 calendar days for serious unexpected suspected adverse reactions (SUSARs) (Correct answer)
Annually, with the IND Annual Report
Only when the FDA requests it
Only at the end of the trial

Correct answer: Within 7 or 15 calendar days for serious unexpected suspected adverse reactions (SUSARs)

Fatal or life-threatening unexpected SUSARs must be reported within 7 calendar days; other serious unexpected SUSARs within 15 calendar days.

Question 53: Which regulatory strategy tool is MOST useful for systematically mapping global market entry requirements across multiple regions?

GANTT chart
SWOT analysis
Product risk profile
Regulatory intelligence matrix (Correct answer)

Correct answer: Regulatory intelligence matrix

A regulatory intelligence matrix organizes country-specific requirements, timelines, and submission formats, enabling strategic comparison across target markets.

Question 54: Which of the following best describes the concept of 'mutual recognition' in the EU regulatory system?

A procedure where one member state's marketing authorization is recognized and extended to other member states (Correct answer)
A reciprocal agreement between the EU and US to share safety data
A process by which CHMP reviews all national authorizations
All EU countries must accept EMA-approved products without review

Correct answer: A procedure where one member state's marketing authorization is recognized and extended to other member states

The Mutual Recognition Procedure (MRP) allows a marketing authorization granted by one EU Reference Member State to be recognized and extended to other Concerned Member States.

Question 55: Under the EU MDR (Regulation 2017/745), which class of medical devices requires involvement of a Notified Body for conformity assessment?

Class I devices only when sterile or measuring
Class IIa, IIb, and III devices (Correct answer)
Class III devices only
All classes including Class I non-sterile, non-measuring devices

Correct answer: Class IIa, IIb, and III devices

Under EU MDR, Class IIa, IIb, and III devices all require a Notified Body for conformity assessment; most Class I devices use manufacturer self-declaration.

Question 56: Under 21 CFR Part 312, what is the maximum period an IND may remain on clinical hold before the FDA must provide written explanation?

90 days
60 days
120 days
30 days (Correct answer)

Correct answer: 30 days

FDA must notify the sponsor in writing of a clinical hold within 30 days of receiving the IND or amendment.

Question 57: Which IND type allows a sponsor to ship an investigational drug to clinical investigators without a 30-day FDA review period?

Treatment IND
Emergency IND (Correct answer)
Exploratory IND
Investigator-initiated IND

Correct answer: Emergency IND

An Emergency IND allows FDA to authorize use over the phone before submission, bypassing the standard 30-day waiting period.

Question 58: A CAPA system investigation concludes with 'no root cause identified.' What is the most appropriate next step?

Close the CAPA and file the record
Document the investigation limitations and implement interim controls pending further recurrence data (Correct answer)
Escalate to senior management for administrative closure
Initiate a recall as a precautionary measure

Correct answer: Document the investigation limitations and implement interim controls pending further recurrence data

When root cause cannot be identified, interim controls and monitoring for recurrence should be documented while the investigation remains open or is carefully closed with justification.

Question 59: A manufacturer discovers that field devices have been modified by users in a way not described in labeling and that caused adverse events. For MDR purposes, this responsibility:

May still require manufacturer reporting if the original device design contributed to the problem (Correct answer)
Is transferred to the distributer who sold the device
Shifts entirely to the user facility
Is waived because the modification was unauthorized

Correct answer: May still require manufacturer reporting if the original device design contributed to the problem

Manufacturers must evaluate whether the device's design or labeling contributed to the adverse event even if unauthorized modifications were involved, and report accordingly.

Question 60: Which regulatory strategy is most appropriate when a company needs to launch a product simultaneously in the US, EU, and Japan?

Global regulatory harmonization strategy using ICH guidelines (Correct answer)
Delegating each region to separate uncoordinated teams
Sequential submissions to each region independently
Prioritizing the largest market first before others

Correct answer: Global regulatory harmonization strategy using ICH guidelines

A global harmonization strategy leveraging ICH guidelines enables concurrent submissions across regions by aligning data packages to shared standards.

Question 61: Under FDA regulations, what distinguishes 'labeling' from 'label' for a drug product?

Labeling and label are legally synonymous terms under 21 USC 321
Labeling applies only to OTC products, while label applies to prescription drugs
Labeling refers only to the package insert, while the label is the outer carton
Labeling encompasses all written, printed, or graphic matter accompanying the article, while the label is only the immediate container (Correct answer)

Correct answer: Labeling encompasses all written, printed, or graphic matter accompanying the article, while the label is only the immediate container

Under 21 USC 321(m), 'labeling' is broader than 'label' and includes all written material accompanying the product, including brochures and websites.

Question 62: Which term describes the process by which FDA orders a manufacturer to conduct post-market surveillance under Section 522 of the FD&C Act?

Warning letter
522 Order (Correct answer)
Consent decree
PMA supplement requirement

Correct answer: 522 Order

FDA issues a 522 Order (referencing Section 522 of the FD&C Act, codified at 21 CFR Part 822) to require post-market surveillance for certain Class II and III devices.

Question 63: Under 21 CFR Part 101, which statement about the Nutrition Facts panel serving size is correct?

Serving size must reflect the amount typically consumed in one sitting based on Reference Amounts Customarily Consumed (RACC) (Correct answer)
Serving size must always equal the entire package contents
Serving size is set by the manufacturer based on marketing preferences
Serving size is determined solely by caloric content of the food

Correct answer: Serving size must reflect the amount typically consumed in one sitting based on Reference Amounts Customarily Consumed (RACC)

FDA requires serving sizes to reflect RACC values so consumers can make realistic comparisons between similar products.

Question 64: A regulatory affairs professional must submit a Field Alert Report (FAR) under 21 CFR 314.81. What triggers a FAR submission?

Any customer complaint about product quality regardless of severity
Any change to the approved manufacturing process
Information concerning any incident that causes the drug product to be mistaken for or adulterated, or which may cause death or serious injury (Correct answer)
Annual summary of all distributed lot recalls

Correct answer: Information concerning any incident that causes the drug product to be mistaken for or adulterated, or which may cause death or serious injury

FARs must be submitted within 3 business days for incidents involving mixups, contamination, significant chemical or physical changes, or labeling errors with potential for harm.

Question 65: Under ICH E8(R1), which approach is emphasized for clinical trial design in regulatory strategy?

Risk-based and fit-for-purpose design tailored to the specific question (Correct answer)
Largest possible sample size to ensure statistical power
Randomized controlled trials as the only acceptable design
Adaptive designs requiring fewer patients

Correct answer: Risk-based and fit-for-purpose design tailored to the specific question

ICH E8(R1) emphasizes a risk-proportionate, fit-for-purpose approach to clinical study design that focuses on quality factors critical to the study's objectives.

Question 66: Which international regulatory body issues the International Nonproprietary Name (INN) for pharmaceutical substances?

International Organization for Standardization (ISO)
ICH Steering Committee
World Health Organization (WHO) (Correct answer)
United States Adopted Names (USAN) Council

Correct answer: World Health Organization (WHO)

The WHO Expert Group on INN is responsible for selecting, reviewing, and publishing International Nonproprietary Names for pharmaceutical substances globally.

Question 67: A biologics manufacturer files a Biologics License Application (BLA). Under which regulatory authority is a BLA reviewed, as distinct from an NDA?

Section 505 of the FD&C Act
Section 510(k) of the FD&C Act
Section 515 of the FD&C Act
Section 351 of the Public Health Service (PHS) Act (Correct answer)

Correct answer: Section 351 of the Public Health Service (PHS) Act

BLAs for biological products are regulated under Section 351 of the Public Health Service Act, while NDAs are regulated under Section 505 of the FD&C Act.

Question 68: In EU regulatory strategy, the primary purpose of a Scientific Advice procedure with EMA is:

To obtain binding commitments on approval timelines
To negotiate pricing and reimbursement terms
To replace the CHMP review process for urgent products
To gain EMA guidance on data requirements before a marketing authorization application (Correct answer)

Correct answer: To gain EMA guidance on data requirements before a marketing authorization application

EMA Scientific Advice provides non-binding guidance on the data package and study designs needed to support a future marketing authorization application.

Question 69: A regulatory affairs team is preparing a risk-based submission strategy for a novel medical device. Which factor MOST influences the choice between a 510(k) and a PMA pathway?

The level of risk the device poses to patients (Correct answer)
Device manufacturing location
Market size of the intended indication
The number of intended users

Correct answer: The level of risk the device poses to patients

The FDA classification system and associated submission pathway (510(k) vs. PMA) are primarily determined by the risk level of the device to patients.

Question 70: Which clinical trial phase is primarily designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a new drug in a small number of healthy volunteers or patients?

Phase 3
Phase 2b
Phase 2a
Phase 1 (Correct answer)

Correct answer: Phase 1

Phase 1 trials are first-in-human studies focused on safety, tolerability, PK/PD, and dose range finding in small groups (typically 20–100 subjects).

Question 71: A company wants to make a manufacturing change to an approved NDA product that has 'substantial potential' to adversely affect drug identity, strength, quality, purity, or potency. What submission is required?

Annual Report
Changes Being Effected (CBE-30) supplement
Prior Approval Supplement (PAS) (Correct answer)
Notification letter only

Correct answer: Prior Approval Supplement (PAS)

Changes with substantial potential to affect product quality require a Prior Approval Supplement, which must be approved by FDA before the change is implemented.

Question 72: A cosmetic product's label lists 'fragrance' as a single ingredient. Under current US regulations, is this compliant?

Yes, fragrance may be listed as a single ingredient under 21 CFR 701.3(a) without disclosing individual components (Correct answer)
Only for products marketed exclusively to professional salons
No, all fragrance components must be individually listed by INCI name
Only if the product contains fewer than five fragrance chemicals

Correct answer: Yes, fragrance may be listed as a single ingredient under 21 CFR 701.3(a) without disclosing individual components

Current US cosmetic regulations under 21 CFR 701.3 allow 'fragrance' as a collective term, though the Modernization of Cosmetics Regulation Act of 2022 introduced new fragrance allergen disclosure requirements.

Question 73: Under GCP, a Certificate of Analysis (CoA) for an investigational drug product must be retained by the:

FDA district office
Investigator at the site as part of the investigator site file (Correct answer)
Subject's primary care physician
IRB for the duration of the trial

Correct answer: Investigator at the site as part of the investigator site file

The CoA for investigational product must be maintained in the investigator site file (Trial Master File) per ICH E6 essential documents requirements.

Question 74: A device manufacturer operating under a 21 CFR Part 822 postmarket surveillance order must submit their surveillance plan to FDA within how many days of receiving the order?

60 days
120 days
90 days (Correct answer)
30 days

Correct answer: 90 days

Under 21 CFR Part 822, manufacturers must submit a postmarket surveillance plan to FDA within 30 days of receiving the surveillance order.

Question 75: Which ICH guideline specifically addresses the stability testing of new drug substances and products?

ICH Q9
ICH Q10
ICH Q1A(R2) (Correct answer)
ICH Q8

Correct answer: ICH Q1A(R2)

ICH Q1A(R2) provides guidance on stability testing conditions, protocols, and data interpretation for new drug substances and products.

Question 76: What is the role of a Reference Listed Drug (RLD) in the ANDA (generic drug) approval process?

It is the FDA-designated comparator used only in pediatric studies
It is the first generic product approved for a given indication
It replaces the innovator drug once the patent expires
It serves as the benchmark to which the generic applicant must demonstrate bioequivalence (Correct answer)

Correct answer: It serves as the benchmark to which the generic applicant must demonstrate bioequivalence

The RLD is the approved brand-name drug to which a generic applicant must demonstrate bioequivalence in an ANDA submission.

Question 77: Which of the following is NOT a recognized class of recall under FDA's classification system?

Class III — unlikely to cause adverse health consequences
Class II — may cause temporary or medically reversible adverse health consequences
Class I — reasonable probability of serious adverse health consequences or death
Class IV — defects with no health risk that do not require notification (Correct answer)

Correct answer: Class IV — defects with no health risk that do not require notification

FDA uses only Class I, II, and III recall classifications; there is no Class IV recall designation.

Question 78: Under ICH Q10, what is the role of 'knowledge management' in a pharmaceutical quality system?

To track employee training completion records
To ensure regulatory submissions are archived correctly
To capture, share, and apply product and process knowledge throughout the product lifecycle (Correct answer)
To manage intellectual property and patent filings

Correct answer: To capture, share, and apply product and process knowledge throughout the product lifecycle

ICH Q10 positions knowledge management as a key enabler that supports acquisition, analysis, storage, and dissemination of product and process knowledge across the product lifecycle.

Question 79: Which metric is MOST useful for tracking the efficiency of a regulatory affairs team's submission planning process over time?

Cycle time from dossier lock to submission date (Correct answer)
Total pages submitted per application
Number of regulatory staff headcount
Number of agency meetings attended annually

Correct answer: Cycle time from dossier lock to submission date

Cycle time from dossier lock to submission measures the internal efficiency of the submission preparation process and can reveal process bottlenecks.

Question 80: Under GCP (ICH E6(R2)), who holds primary responsibility for the conduct of a clinical trial at an investigational site?

The sponsor's monitor
The principal investigator (Correct answer)
The IRB/IEC
The contract research organization (CRO)

Correct answer: The principal investigator

ICH E6(R2) assigns primary responsibility for the conduct of the trial at a site to the principal investigator (PI).

Question 81: What does the term 'qualification' refer to in the context of GMP equipment validation?

Confirming that suppliers meet quality standards
Verifying that analytical methods are suitable for their intended use
Documenting that a process consistently produces a product meeting specifications
Demonstrating that equipment is properly installed, operates correctly, and performs as intended (Correct answer)

Correct answer: Demonstrating that equipment is properly installed, operates correctly, and performs as intended

Equipment qualification (IQ/OQ/PQ) demonstrates that equipment is installed correctly, operates as designed, and performs consistently within specified parameters.

Question 82: Why is strategic planning important in regulatory affairs?

To increase manufacturing speed
To align regulatory goals with company strategy (Correct answer)
To bypass regulatory reviews
To avoid documentation

Correct answer: To align regulatory goals with company strategy

Strategic planning in regulatory affairs is crucial for integrating regulatory requirements and timelines into the overall business objectives of a company. It ensures that product development, market entry, and lifecycle management are conducted in a way that is compliant, efficient, and supports the company's commercial goals. This alignment helps avoid delays, optimize resource allocation, and achieve successful market access.

Question 83: A PMS plan should define data sources, evaluation methods, and thresholds for action. Which element is MOST critical for triggering a CAPA?

Competitor product complaint data only
Pre-defined signal detection thresholds based on risk (Correct answer)
The manufacturer's annual revenue targets
Historical warranty replacement averages

Correct answer: Pre-defined signal detection thresholds based on risk

Pre-defined, risk-based signal thresholds ensure that PMS data triggers corrective action objectively, before problems escalate.

Question 84: When conducting trend analysis on PMS data, which statistical approach is typically used to identify a statistically significant increase in adverse event rates?

Pareto analysis of product color variants
Control charts (SPC) comparing current rates to historical baseline (Correct answer)
Simple bar graphs of raw complaint counts over time
Linear regression of total sales revenue

Correct answer: Control charts (SPC) comparing current rates to historical baseline

Statistical Process Control charts allow manufacturers to detect signals that exceed normal variation, objectively flagging when rates have moved beyond expected limits.

Question 85: Which form is submitted to the FDA to report an adverse drug event?

Form FDA 1571
Form FDA 356h
Form FDA 3500 (Correct answer)
Form 483

Correct answer: Form FDA 3500

Form FDA 3500, also known as the MedWatch Voluntary Reporting Form, is the primary form used by healthcare professionals and consumers to report serious adverse events, product problems, or quality issues with medical products. This includes drugs, biologics, and medical devices. It is essential for the FDA's pharmacovigilance efforts to monitor product safety once on the market.

Question 86: When preparing a briefing package for a Pre-Submission (Q-Sub) meeting with the FDA for a new medical device, which of the following is the MOST critical component to include?

Specific, forward-looking questions for the agency on which feedback is sought. (Correct answer)
The final, locked-down version of the device's Instructions for Use (IFU).
Detailed financial projections for the first five years.
A complete list of all anticipated marketing claims.

Correct answer: Specific, forward-looking questions for the agency on which feedback is sought.

The primary purpose of a Q-Submission is to obtain feedback from the agency to guide product development and submission preparation. Therefore, including clear, specific, and well-reasoned questions is the most critical component, as these questions will frame the entire discussion and the feedback provided by the FDA. The other elements, while potentially part of the overall package, are secondary to the core goal of getting answers to specific regulatory, technical, or clinical questions.

Question 87: In the EU regulatory system, what is the 'centralised procedure' for medicinal product authorisation?

A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states (Correct answer)
A mutual recognition process between two or more member states without EMA involvement
A fast-track process exclusively for orphan medicinal products
A procedure where each EU member state independently evaluates and approves a product for its own territory

Correct answer: A single evaluation by the European Medicines Agency (EMA) leading to a marketing authorisation valid in all EU/EEA member states

The centralised procedure results in a single EMA opinion and a European Commission decision granting a marketing authorisation valid across all EU and EEA countries.

Question 88: Under 21 CFR Part 211, which document must be prepared and followed for each batch of drug product?

Device history record
Design history file
Master batch record
Batch production record (Correct answer)

Correct answer: Batch production record

21 CFR 211.188 requires a batch production record prepared for each batch as an accurate reproduction of the master production record.

Question 89: What is the key difference between a 'correction' and a 'removal' under FDA's 21 CFR Part 806?

Corrections apply to Class I devices; removals apply to Class III
Corrections are mandatory; removals are voluntary
Corrections address devices at the point of use or distribution; removals bring devices back to the manufacturer or distributor (Correct answer)
Corrections require FDA approval; removals do not

Correct answer: Corrections address devices at the point of use or distribution; removals bring devices back to the manufacturer or distributor

A correction addresses a device problem at its current location, while a removal involves physically returning the device from the field to the manufacturer or distributor.

Question 90: Under EU MDR 2017/745, what is a 'Field Safety Corrective Action' (FSCA)?

An action taken to reduce risk of death or serious deterioration in health associated with a device already on the market (Correct answer)
An internal audit of the manufacturing process
A scheduled preventive maintenance activity by the manufacturer
A recall initiated solely for commercial reasons

Correct answer: An action taken to reduce risk of death or serious deterioration in health associated with a device already on the market

An FSCA is any action taken to reduce a risk of death or serious deterioration related to a device in use, and must be reported to competent authorities.

Question 91: Which strategy is MOST appropriate when a company seeks regulatory approval in multiple markets with very different data requirements?

Submit only to markets with the most relaxed requirements first, then adapt
Build a core global dossier that meets the most stringent requirements, with market-specific modules appended (Correct answer)
Develop a separate, fully independent dossier for each market from scratch
Use a single country's approval to leverage automatic recognition in all other markets

Correct answer: Build a core global dossier that meets the most stringent requirements, with market-specific modules appended

Building a core global dossier to the highest standard (often ICH CTD format) with modular regional additions is the most efficient multi-market strategy, reducing duplication and inconsistency.

Question 92: In the context of PMS complaint handling, what does 'MDR decisioning' require the manufacturer to document?

The customer's satisfaction score after complaint resolution
The number of social media reposts of the complaint
The rationale for why a complaint does or does not meet MDR reporting criteria (Correct answer)
Marketing strategy changes resulting from the complaint

Correct answer: The rationale for why a complaint does or does not meet MDR reporting criteria

FDA expects written documentation of the analysis and justification used to determine whether each complaint meets MDR reportability thresholds.

Question 93: A biotech company is developing a novel combination medical device for the US market. Early in the development process, the regulatory affairs professional recommends a pre-submission meeting with the FDA. What is the most significant strategic advantage of this early interaction?

To receive a guaranteed approval timeline from the regulatory agency.
To obtain early feedback and clarification on regulatory expectations, potentially avoiding costly delays later. (Correct answer)
To lobby the agency to change existing regulations to favor the new product.
To fulfill the mandatory first step required for all new device submissions.

Correct answer: To obtain early feedback and clarification on regulatory expectations, potentially avoiding costly delays later.

Engaging with regulatory authorities early in the development process is a critical strategic activity. The main benefit is gaining clarity on regulatory expectations, which helps in designing studies and preparing submissions that meet the agency's requirements. This proactive approach can prevent significant delays and resource expenditure that might arise from misunderstandings discovered late in the process. It does not guarantee approval timelines and is not always a mandatory first step, nor is its purpose to lobby for regulatory change.

Question 94: What is the role of a Target Product Profile (TPP) in regulatory strategy?

It specifies the drug's chemical synthesis route for manufacturing
It is a required FDA submission document for all INDs
It replaces the Risk Management Plan (RMP) in EU submissions
It defines the desired product attributes that drive regulatory, clinical, and CMC development decisions (Correct answer)

Correct answer: It defines the desired product attributes that drive regulatory, clinical, and CMC development decisions

The TPP articulates the minimum and ideal characteristics of the final product, aligning all development functions — including regulatory — around shared goals from the outset.

Question 95: A global regulatory team must prioritize which markets to enter first for a new drug. Which combination of factors is MOST relevant to this strategic decision?

Language similarity to the country where the drug was invented
Market size, regulatory timeline, reimbursement environment, and unmet medical need (Correct answer)
Office locations of the company and proximity to manufacturing sites
Number of competing products already approved in each market

Correct answer: Market size, regulatory timeline, reimbursement environment, and unmet medical need

Market prioritization in regulatory strategy balances commercial opportunity (market size, reimbursement), regulatory feasibility (timeline, pathway), and clinical need.

Question 96: A sponsor seeks to enroll a pregnant woman in a Phase II trial of a new antiviral. Under 21 CFR Part 50 Subpart B, this population is classified as:

A vulnerable subject requiring additional safeguards (Correct answer)
A non-regulated population if the condition is life-threatening
An exempt population if consent is obtained from the father
An excluded population under all circumstances

Correct answer: A vulnerable subject requiring additional safeguards

Pregnant women are a vulnerable population under 45 CFR Part 46 Subpart B, requiring additional protections and specific risk-benefit criteria.

Question 97: Which of the following statements BEST distinguishes the Premarket Approval (PMA) pathway from the 510(k) pathway?

The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate. (Correct answer)
510(k) submissions are only for Class I devices, while PMA submissions are for Class II and III devices.
The standard review timeline for a 510(k) is 180 days, whereas for a PMA it is 90 days.
A 510(k) results in an 'approval' letter, while a PMA results in a 'clearance' letter.

Correct answer: The PMA pathway requires a demonstration of safety and effectiveness through clinical data, whereas a 510(k) relies on substantial equivalence to a predicate.

The fundamental difference lies in the evidence required. The PMA process requires manufacturers to provide valid scientific evidence, typically including clinical trial data, to independently demonstrate a reasonable assurance of the device's safety and effectiveness. In contrast, the 510(k) pathway requires a demonstration of substantial equivalence to a legally marketed predicate device, leveraging the predicate's established safety and effectiveness profile.

Question 98: What is the purpose of a 'washout period' in a crossover clinical trial design?

To enrich the study population with responders
To allow subjects to withdraw without penalty
To allow the investigational drug to reach steady state
To eliminate residual effects of the first treatment before administering the second (Correct answer)

Correct answer: To eliminate residual effects of the first treatment before administering the second

A washout period is included between treatment periods in crossover designs to eliminate carryover effects from the preceding treatment.

Question 99: When a company receives a Warning Letter from FDA, what is the typical expected response timeframe?

7 days
30 days (Correct answer)
15 days
60 days

Correct answer: 30 days

FDA Warning Letters typically request a written response within 15 working days (approximately 3 calendar weeks), though 30 calendar days is the common standard timeframe cited.

Question 100: A product is approved in the US but the sponsor plans EU submission. Which ICH guideline is most relevant for planning additional safety studies to address European requirements?

ICH Q8 (Pharmaceutical Development)
ICH Q10 (Pharmaceutical Quality System)
ICH M4 (CTD format)
ICH E1 (Population Exposure) or ICH S6 for specific product types addressing safety database size (Correct answer)

Correct answer: ICH E1 (Population Exposure) or ICH S6 for specific product types addressing safety database size

ICH E1 addresses the extent of patient exposure needed to assess clinical safety, helping sponsors determine if their US safety database is sufficient for EU submission or if additional data is needed.

RAC Regulatory Affairs Certification Exam

The RAC exam, administered by RAPS, certifies regulatory affairs professionals in their knowledge of strategic planning, pre-marketing, post-marketing, and interfacing with regulatory authorities for drugs and devices.

100

Questions

120 min

Time Limit

75%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds